We are building an expansive pipeline of cutting-edge in vivo genome-editing therapies that target ocular, metabolic, and rare diseases at their genetic roots. By editing genes directly in targeted organs and tissues in the body, we aim to cure diseases and improve quality of lives with safe, effective, and long-lasting medical solutions.
